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Early stage laryngeal cancer can be effectively cured by radiotherapy or conservative laryngeal surgery. In the UK, radiotherapy is the
preferred first line treatment. However, up to 25% of patients with T2 tumours will demonstrate locally persistent or recurrent
disease at the original site, requiring salvage surgery to achieve a definitive cure. Patients experiencing treatment failure have a
relatively poor prognosis. A retrospective analysis was conducted consisting of 124 patients with early stage (T1–T2, N0) laryngeal
squamous cell carcinoma. In total, 62 patients who failed radiotherapy were matched for T stage, laryngeal subsite and smoking
history to a group of 62 patients successfully cured by radiotherapy. Using immunohistochemistry the groups were compared for
expression of apoptotic proteins: bcl-2, bcl-XL, bax, bak and survivin. Radioresistant laryngeal cancer was associated with bcl-2
(Po0.001) and bcl-XL (P¼0.005) expression and loss of bax expression (P¼0.012) in pretreatment biopsies. Bcl-2 has an accuracy
of 71% in predicting radiotherapy outcome. The association between expression of bcl-2, bcl-XL and bax with radioresistant cancer
suggests a potential mechanism by which cancer cells avoid the destructive effects of radiotherapy. Predicting radioresistance, using
bcl-2, would allow the clinician to recommend conservative laryngeal surgery as an alternative first line treatment to radiotherapy.
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Head and neck cancers are the sixth most prevalent cancers in the
world with a global incidence of 700000 cases per year (Parkin
et al, 2001). They constitute a heterogeneous group of cancers
arising from the upper aerodigestive tract, paranasal sinuses,
salivary and thyroid glands. In order to avoid tumour hetero-
geneity we have investigated one region, the larynx. This is the
largest head and neck region in the United Kingdom affected by
cancer, with the vast majority of tumours being squamous cell in
origin. Cancer in this region has important functional and
psychological consequences for the patient, in particular with
regard to communication and eating.
Radiotherapy not only cures most early stage, T1 and T2,
laryngeal cancers but it also preserves laryngeal function.
Unfortunately, treatment failures do occur; between 5 and 10%
of stage I and up to 25% of stage II laryngeal cancers are resistant
to radiotherapy (Fernberg et al, 1989; Klintenberg et al, 1996;
Johansen et al, 2002). Patients then require salvage surgery,
typically involving removal of the larynx, in order to achieve
tumour control. The delay in diagnosis following failed radio-
therapy results in tumour progression, which impacts significantly
on patient survival. Salvage surgery is also associated with
increased failure and complication rates due to operating in a
previously irradiated field (McLaughlin et al, 1996).
When a patient presents with head and neck cancer, subsequent
management and treatment is based largely upon the TNM staging
of the tumour. While this system is adequate in predicting group
responses to treatment, there is significant variability between
individual patients within any particular stage. Although there
have been a number of laboratory studies on radioresistance in
early laryngeal cancer, at present there are no predictive molecular
markers in routine use (Smith and Haffty 1999; Yoo et al, 2000;
Cho et al, 2004; Nix et al, 2004a,b).
Radiotherapy results in DNA damage, the most lethal form of
which is a double-strand break (Willers et al, 2004). If the cell is
unable to repair such damage, a type of programmed cell death is
initiated termed apoptosis (Kerr et al, 1994). The Bcl-2 family of
proteins play an important part in a cell’s ability to undergo
apoptosis following radiotherapy damage (Gudkov and Komarova
2003). The antiapoptotic members of the family, bcl-2 and bcl-XL,
and the proapoptotic member bax are reportedly expressed in 15,
74 and 81%, respectively, of laryngeal biopsy samples from
advanced laryngeal tumours (Trask et al, 2002). Bcl-2 over-
expression, in relation to radiotherapy treatment failures, has also
been reported in cervical (Mukherjee et al, 2001), prostate, bladder
(Pollack et al, 1997), rectal (Schwandner et al, 2000) and non-
small-cell-lung cancer (Hwang et al, 2001). In a study of eight cases
of radioresistant laryngeal cancer and 13 cases of radiosensitive
cancer, the expression of key proteins involved in DNA damage
recognition (p53), cell cycle arrest (ATM, p16 and p21/WAF1) and
apoptosis (bcl-2 and bax) was studied. Bcl-2 was found to be
significantly associated with radioresistant tumours (P¼0.03)
(Condon et al, 2002).
Antiapoptotic members of the Bcl-2 family of proteins, such
as bcl-2 and bcl-XL, prevent cytochrome c release from the
mitochondrial membrane. Proapoptotic members, such as bax and
bak, cause the release of cytochrome c (Wei et al, 2001). Once
cytochrome c is released into the cytosol, it activates procaspase 9
resulting in an enzymatic cascade that eventually activates the
effector caspases 3, 6 and 7. Caspases are an important family
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sof proteases responsible for effecting programmed cell death.
They are activated in response to excessive cell stress such as
radiotherapy induced DNA damage (Mow et al, 2001). The Bcl-2
family also controls the release of apoptosis inducing factor (AIF)
and EndoG nuclease from the mitochondria (Susin et al, 1999).
This control is again partly dependent upon relative concentra-
tions of the family members. AIF and EndoG nuclease migrate into
the cell nucleus and cause chromatin condensation and DNA
fragmentation. This apoptotic pathway is independent of cyto-
chrome c and occurs following radiotherapy induced cell damage
(Ravi and Bedi, 2002). Survivin is a member of the inhibitors of the
apoptosis family. It functions downstream of the Bcl-2 family by
inhibiting the actions of caspases 3 and 7 (Tamm et al, 1998).
Overexpression of survivin has been associated with radio-
resistance in colorectal cell lines (Rodel et al, 2003).
On the basis of these observations we have investigated the
relationship between members of the Bcl-2 family (bcl-2, bcl-XL,
bax, bak) and survivin with radioresistant laryngeal cancer.
MATERIALS AND METHODS
Study population and definitions
Local Research Ethics Committees’ approval was obtained for the
study using archival biopsy material. Two groups of patients with
laryngeal carcinoma, treated with curative intent by 55–60Gy of
radiotherapy in 20–25 fractions, were retrospectively identified
from databases held in ENT Departments in England. Following
completion of single modality radiotherapy, all patients were
followed up in a Head and Neck Oncology Clinic. Patients were
reviewed on a monthly basis during the first year, a bimonthly
basis in the second year and every 3 months during the third year.
One group consisted of patients with radioresistant laryngeal
tumours and the other group with radiosensitive tumours.
The criteria for a radioresistant tumour was the following:
(1) Radiotherapy had to be given as a single modality treatment
with curative intent for a biopsy proven squamous cell
carcinoma of the larynx.
(2) Biopsy proven recurrent squamous cell carcinoma occurring
at the original anatomical site, within 12 months of finishing a
course of radiotherapy.
The criteria for a radiosensitive tumour was the following:
(1) Biopsy proven squamous cell carcinoma of the larynx resulted
in single modality treatment with radiotherapy.
(2) Post-treatment, patients had a minimum follow up of 3 years
following completion of radiotherapy with no evidence of
recurrence at the original site of the tumour.
In order to reduce confounding variables, the two groups were
matched with regard to laryngeal T stage, glottic or supraglottic
cancer subsite and smoking history. Each group consisted of 62
patients comprising 44 T1- and 18 T2-staged laryngeal squamous
cell carcinomas (Table 1). Clinically all tumours were N0 and M0 at
the time of treatment, according to the American Joint Committee
on Cancer classification 2002 (Greene and Sobin, 2002). In total, 56
tumours occurred in the glottic and six in the supraglottic subsites
in each group.
Procedure
Tissue sections were taken from pretreatment archival tissue
blocks and immunohistochemical techniques were used to detect
the apoptotic markers bcl-2, bcl-XL, bax, bak and survivin. The
avidin biotin method, as previously described (Cawkwell et al,
1999), allowed the immunohistochemical detection of the mono-
clonal antibodies: anti-bcl-2 at a dilution of 1:50 (Neomarkers,
Fremont, USA: Ab-1 clone 100/D5), anti-bcl-XL at a dilution of
1:75 (Neomarkers: Ab-2 clone 7D9), anti-bax at a dilution of 1 in
75 (Neomarkers: Ab-5 clone 2C8), anti-survivin at a dilution of 1 in
50 (Santa Cruz Biotechnology, USA FL-142) and the polyclonal
antibody anti-bak at a dilution of 1:50 (Neomarkers Ab-2). The
negative control for each marker was to omit the primary
antibody. Immunohistochemistry was performed in batches of 50
with equal radioresistant and radiosensitive samples in each batch
in order to minimise any influence of assay run on variability.
Two investigators performed marker scoring independently,
with the radiotherapy treatment outcome blinded to the scorers. If
consensus agreement could not be reached, a third opinion was
taken. In order to reduce sampling error, the whole pretreatment
laryngeal tumour biopsy was assessed for antibody staining.
Intensity of marker staining was not used as a method for scoring
the tissue sections because the degree of antigen masking is
dependent upon the fixative used, its degree of penetration and the
fixation time. Such factors may vary between clinical samples and
as a consequence are difficult to control for. Laryngeal tumour
sections were regarded as positive only if more than 5% of the
tumour cells displayed the staining when viewed by light
microscopy at  200 magnification. Sections with 5% or less of
the tumour staining were considered negative. This simple positive
or negative scoring system used to interpret the antibody staining
patterns has previously been reported and results in high degree
of interobserver agreement (Mighell et al, 1998). In this study‘, the
two independent assessors had complete agreement in 100% of the
bak, bad and survivin cases. For bcl-2 and bcl-XL, the two assessors
had complete agreement in 90 and 87% of the cases, respectively,
and consensus agreement was achieved for all cases.
Statistical analysis
w
2 statistical analysis using two by two contingency tables with one
degree of freedom was used to calculate significance. All P-values
quoted are for two-sided significance, between the radioresistant
and radiosensitive groups with values less than 0.05 being
considered significant. Multiple regression analysis was performed
using SPSS v11.5 (SPSS Inc.). Marker accuracy, sensitivity and
specificity were calculated as previously reported (Greenhalgh,
1997).
Table 1 Radioresistant and radiosensitive patient profiles
Radioresistant patients Radiosensitive patients
(N¼62) (N¼62)
T1 staged tumour
Glottic 42 42
Supraglottic 2 2
T2 staged tumour
Glottic 14 14
Supraglottic 4 4
Histological grade
Well 19 20
Moderate 35 30
Poor 8 12
Gender
Female 8 10
Male 54 52
Average age (years) 64 62
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The radioresistant group consisted of 62 patients with laryngeal
squamous cell carcinoma (Table 1). The average age of the patient
at diagnosis was 64 with a range of 45–87 years. The mean time to
tumour recurrence was 6.2 months with a range of 2–12 months.
The average age of the radiosensitive group was 62 with a range of
40–87 years. All radiosensitive tumours had been followed up for
at least 3 years with no evidence of a recurrent tumour. There was
no significant difference in tumour differentiation (P¼0.543) or
gender (P¼0.610) between the two groups (Table 1).
Bak staining was localised to the cytoplasm of the tumour and
was present in all radioresistant and radiosensitive tumours.
Survivin expression was also present in all radioresistant and
radiosensitive tumours, displaying a cytoplasmic and nuclear
distribution (Table 2).
Bcl-2 and bcl-XL staining was localised to the tumour cell
cytoplasm. Intense staining was also evident in stromal lympho-
cytes. Bax staining was diffusely present in the cytoplasm of
tumour cells and localised in a granular pattern in the cell nucleus.
Again this staining pattern was also present in stromal lympho-
cytes.
In total, 53% of radioresistant tumours expressed bcl-2
compared with 11% in the radiosensitive group (Po0.001). Bcl-XL
was expressed by 91% of the radioresistant tumours compared
with 73% of the radiosensitive tumours (P¼0.005). In total, 43%
of radioresistant tumours expressed bax compared with 66% in the
radiosensitive group (P¼0.012). Radioresistant tumours were
associated with expression of the antiapoptotic markers bcl-2 and
bcl-XL and underexpression of the proapoptotic marker bax
(Table 2).
The coexpression of the apoptotic markers, bcl-2, bcl-XL and
bax in radioresistant laryngeal cancer, is displayed in Table 3. The
main findings are that 50% of the radioresistant samples expressed
both bcl-2 and bcl-XL, while only 5% of the tumours were negative
for both markers. Bcl-2 expression and loss of bax expression was
seen in 31% of the radioresistant tumours. Bcl-XL expression and
loss of bax expression was seen in 50% of the radioresistant
tumours.
Multivariate regression analysis using treatment failure as the
dependent factor and bcl-2, bcl-XL, bax, bak, survivin, tumour
differentiation as covariants demonstrated that bcl-2 (Po0.001),
bcl-XL (P¼0.007) and bax (P¼0.014) were independent variables.
In this series, bcl-2 expression has an accuracy of 71% in
predicting the outcome of radiotherapy with a sensitivity of 53%
and a specificity of 89% (Table 4). Bcl-2 has been chosen as a
predictor of radioresistance in preference to bcl-XL or bax due to
its low false positive rate of 11%.
DISCUSSION
At present, a clinical equipoise exists in the management of early
stage laryngeal cancer. Radiotherapy and conservative endo-
laryngeal surgery are currently used to obtain a cure, with no
published randomised controlled trials to suggest the most
effective modality (Dey et al, 2002). Treatment choice usually
depends upon local available expertise and the physician’s
preference for treatment options. Using markers that can predict
the radioresistance of a tumour would enable the TNM staging
system to be refined and allow tailored cancer treatments to be
devised for each patient.
Each head and neck region has its own TNM staging system
(Greene and Sobin, 2002), such that a T1 tumour in one region is
not comparable to similar staged tumours in other regions with
regard to treatment regimes and treatment failure rates (BAO-
HNS, 2002). Investigating radioresistance using heterogeneous
tumour groups has led to conflicting published results. To date,
cellular and molecular markers of radioresistance in head and neck
cancer have failed to improve the accuracy of the TNM system (Nix
et al, 2004a). In order to address this issue we have assembled a
large homogeneous series of radioresistant laryngeal cancers. As
Table 2 Expression pattern of bcl-2, bcl-XL, bax, bak and survivin
Marker
Radioresistant
tumour
numbers (62)
Radiosensitive
tumour
numbers (62) P value
a
bcl-2 positive 33 (53%) 7 (11%) Pp0.001
bcl-2 negative 29 (47%) 55 (89%)
bcl-XL positive 57 (91%) 45 (73%) P¼0.005
bcl-XL negative 5 (9%) 17 (27%)
bax positive 27 (43%) 41 (66%) P¼0.012
bax negative 35 (57%) 21 (34%)
bak positive 62 (100%) 62 (100%)
bak negative 0 0
survivin positive
b 37 (100%) 37 (100%)
survivin negative 0 0
aw
2 test, two-sided significance.
bn¼37.
Table 3 Marker expression in 62 radioresistant laryngeal cancers
Bcl-XL
Negative stain Positive stain
Bcl-2 negative stain 3 (5%)
a 26 (42%)
Bcl-2 positive stain 2 (3%) 31 (50%)
Bax
Negative stain Positive stain
Bcl-2 negative stain 16 (26%) 13 (21%)
Bcl-2 positive stain 19 (31%) 14 (23%)
Bax
Negative stain Positive stain
Bcl-XL negative stain 4 (6%) 1 (2%)
Bcl-XL positive stain 31 (50%) 26 (42%)
aPercentages quoted are based on the cohort of 62 radioresistant tumours.
Table 4 Predictive value of bcl-2 as a marker of radiotherapy outcome in
124 patients
Final outcome of therapy
Bcl-2 staining Tumour recurrence¼62 Tumour free¼62
Positive¼40 True +ve¼33 False +ve¼7
Negative¼64 False  ve¼29 True +ve¼55
Sensitivity 53%
Specificity 89%
Positive predictive value 83%
Negative predictive value 65%
Accuracy 71%
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sthere is no universal definition of radioresistant cancer, we have
devised a strict definition. By stipulating that recurrences have to
occur within 12 months of finishing radiotherapy, second primary
tumours are very unlikely to be counted as an erroneous
radiotherapy recurrence. Second primary cancers are frequent in
head and neck regions, occurring at a rate of 7% per year following
the index case (Holland et al, 2002). In addition, we have only used
pretreatment archival biopsy material in the study. This is to avoid
any effects that radiotherapy may have on the markers under
investigation. As this is a nonrandomised retrospective review,
we have tried to minimise confounding variables by matching
the groups as closely as possible for TNM stage, laryngeal
subsite, smoking history, gender and radiotherapy dose and
schedule.
We have used a simple method to evaluate the immunohisto-
chemical staining pattern, as opposed to semiquantitative scales
based on intensity; this is because intensity is partly dependent
upon the formalin fixation procedure (Fisher et al, 1994).
This study demonstrates that there is a differential expression of
the Bcl-2 family members between radioresistant and radio-
sensitive laryngeal cancer. The majority of early stage laryngeal
cancers are radiosensitive. As a consequence, our radiosensitive
tumours should be similar to reported series that do not
differentiate radioresistant and radiosensitive tumours. The over-
expression of bax (66%) and the under expression of bcl-2 (11%)
and bcl-XL (73%), in our radiosensitive series, are similar to
reported results in other laryngeal series looking at apoptotic
marker expression (Trask et al, 2002). In contrast, there is a
statistically significant difference in bcl-2 (53%) and bcl-XL (91%)
expression and bax (43%) underexpression in our radioresistant
group compared to the radiosensitive group.
The Bcl-2 family members all possess at least one of four
conserved functional motifs, which allows hetero- and homo-
dimerisation between family members. When dimerisation occurs
between pro- and antiapoptotic members, their action is effectively
neutralised (Wei et al, 2001). As a consequence, the relative
concentrations of the family members are one way that the
apoptotic machinery is regulated (Ravi and Bedi, 2002). This may
explain the differential distribution of markers between the two
groups. In this study, the Bcl-2 family members that oppose
apoptosis are significantly associated with the radioresistant
tumour specimens. The overexpression of bcl-2 and bcl-XL
proteins by the tumour cells may create a block to radiotherapy-
induced apoptosis. As a consequence, the tumour becomes
relatively radioresistant. Also by downregulating the level of the
proapoptotic Bcl-2 family member, bax, radiotherapy-induced
apoptosis will be further inhibited.
As early stage laryngeal tumours can be effectively cured by
either conservative laryngeal surgery or radiotherapy (Ton-Van
et al, 1991), predicting which tumours are radioresistant means
that these patients can be offered a surgical option initially. In the
UK approximately 2300 patients develop laryngeal cancer (BAO-
HNS, 2002), of which 1150 will be treated with radiotherapy; and of
these up to 287 (25%) will be radioresistant. At present, the
clinician cannot predict any of the above radiotherapy treatment
failures. However, using bcl-2, we can predict 152 (53%) of the
failures and offer these patients conservative laryngeal surgery
instead of radiotherapy. Conservative laryngeal surgery is an
established technique, widely used in the USA and Europe as a
first-line treatment for early stage laryngeal cancer (BAO-HNS,
2002); hence, such patients will benefit from improved survival
and quality of life as their larynx will be preserved and they will not
have to receive unnecessary radiotherapy. Equally, there will be no
detrimental effect to the 11% of patients with a false positive bcl-2
result, who will be offered conservative laryngeal surgery instead of
radiotherapy.
By identifying the mechanism that tumour cells develop,
radioresistance novel treatment therapies may be developed.
Antisense oligonucleotides targeting bcl-2 have been used to
reduce the expression of bcl-2 in phase 1 clinical trials with
lymphomas (Waters et al, 2000). This strategy could be used to
reduce the expression of bcl-2 or bcl-XL in cancers that are
predicted to be radioresistant. This therapy may then lead to a
more radio-responsive tumour. Such a strategy is highly likely to
be beneficial for bcl-2 positive advanced stage laryngeal tumours
that are currently managed with combination surgery and radio-
therapy or combined chemo-radiotherapy.
By studying a homogeneous group of head and neck cancer,
using a strict definition of radioresistance to avoid confounding
factors, we have demonstrated that expression of antiapoptotic
members, bcl-2 and bcl-XL, and underexpression of proapoptotic
marker, bax, are associated with radioresistance. By only studying
pretreatment biopsy samples, bcl-2 has a 71% accuracy in
predicting patient response to radiotherapy. These observations
now require verification in larger-scale prospective trials. Case–
control studies rely on retrospective records and there may be
confounding study factors, which can be more closely controlled in
a prospective clinical trial. Ideally, a randomised controlled trial
between radiotherapy and conservative endolaryngeal surgery
would also address the issue that bcl-2 predicts radioresistance as
opposed to just being a marker of poor outcome. If verified, Bcl-2
positive patients could be offered an established and equally
effective alternative treatment to radiotherapy, resulting in
improved patient survival and quality of life.
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